Investment
Features
FeesSafety
Academy
More
Pluang+

Mizuho says Circle's USDC growth and competition risks remain despite bank approval

Market News
13 Jul 2026
Coindesk
View Source
Neutral
pluang ai news

Japanese bank Mizuho maintains a neutral rating on Circle despite its recent approval to establish a national trust bank. The approval is seen as a positive step but does not resolve key challenges such as the decline in USDC's market capitalization since March 2026 and increasing competition from new stablecoins like Open USD. USDC's supply has fallen significantly, raising concerns about its growth and revenue outlook. The emergence of consortium-backed stablecoins could further pressure Circle's market position, leading Mizuho to stay cautious on the stock.

More News

Noble Capital Markets starts coverage on VivoPower with Outperform rating and $10 target

Noble Capital Markets starts coverage on VivoPower with Outperform rating and $10 target

Noble Capital Markets has initiated equity research coverage on VivoPower PLC, assigning an Outperform rating and setting a price target of $10. VivoPower is a B Corp-certified global developer of powered land and data center infrastructure for AI ap...

Analyst Insights
Bullish
2 hours ago
Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.

Head and neck squamous cell carcinoma market to grow 10.5% CAGR through 2036 with new immunotherapies.

The head and neck squamous cell carcinoma (HNSCC) market is projected to grow at a 10.5% CAGR from 2026 to 2036, driven by rising cancer incidence and new immunotherapy launches. Key emerging therapies from companies like Johnson & Johnson, BioNTech,...

Market News
Bullish
2 hours ago
Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.

Alamar Biosciences launches national study analyzing 21,000 plasma samples to advance Alzheimer's biomarkers.

Alamar Biosciences has partnered with top U.S. research universities to start a nationwide proteomics project using its NULISAseq™ Neuro 220 panel. The study will analyze about 21,000 plasma samples from 10,000 Alzheimer's and related dementia partic...

Market News
Bullish
2 hours ago
Alamar Biosciences launches national study using blood tests to advance Alzheimer's biomarker research.

Alamar Biosciences launches national study using blood tests to advance Alzheimer's biomarker research.

Alamar Biosciences has partnered with leading U.S. universities to launch a nationwide proteomics study analyzing around 21,000 plasma samples from 10,000 Alzheimer's and related dementia patients. Using its NULISAseq™ Neuro 220 test kit, the project...

Market News
Bullish
2 hours ago
VINCI repurchases 400,000 shares between July 6-10, 2026, at an average price of €121 each.

VINCI repurchases 400,000 shares between July 6-10, 2026, at an average price of €121 each.

VINCI SA announced it repurchased a total of 400,000 treasury shares from July 6 to July 10, 2026, under authorization from its April 2026 General Meeting. The shares were bought at an average weighted price of approximately €120.99 per share across ...

Company Fundamentals
Neutral
4 hours ago
banner-footerbanner-footer

Invest & Trade with
#1 Award-Winning Investment Super App